RE: Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

摘要

BRCA1/2 mutations play a predictive role in ovarian cancer risk evaluation. Moreover, patients are today being tested for mutations to select a tailored therapy because they could benefit from a treatment with PARP inhibitors (PARPis). Therefore, in ovarian carcinomas (OCs), mutation testing is an important step in planning the correct therapeutic strategy in association with chemotherapy and anti–vascular endothelial growth factor agents. We read with great interest the recent article in the Journal by Vos et al. ( ) that investigates the role of universal tumor DNA testing of all newly diagnosed OC patients as prescreen for PARPi treatment and cancer predisposition. With the approach described by the authors, hereditary as well as somatic aberrations affecting DNA could be quickly and correctly detected with tumor single-molecule molecular inversion, probe-based, next-generation sequence testing. The authors concluded that this test, as the first step in all newly diagnosed OC patients, could statistically significantly increase the identification rate of eligible patients for treatment with PARPis. Even if this result can contribute to modifying clinical practice, it is appropriate to make some observations.